Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Blusewicz

Obstetrics & Gynecology Bluffton, SC Medical Doctor

NPI 1467486456 CMS profile 111083

29 Plantation Park Dr Ste 401, Bluffton, SC 29910

Open in the dashboard

General payments

$12,314

281 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Blusewicz of Bluffton, SC is reported in the CMS Open Payments database as having received $12,314 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,106 46
2024 General $7,103 42
2023 General $602 35
2022 General $1,216 50
2021 General $1,267 57
2020 General $378 23
2019 General $643 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Blusewicz
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Tracy Blusewicz were reported at $1,106. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Tracy Blusewicz Obstetrics & Gynecology median Middle half National median
2019 $643 $172 $62–$391 $163
2020 $378 $94 $36–$222 $114
2021 $1,267 $136 $42–$369 $132
2022 $1,216 $160 $50–$433 $149
2023 $602 $169 $56–$423 $160
2024 $7,103 $152 $50–$371 $164
2025 $1,106 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $7,521 57 payments
  2. Galderma Laboratories, L.P. $660 15 payments
  3. Mayne Pharma Inc. $443 26 payments
  4. TherapeuticsMD, Inc. $408 24 payments
  5. Astellas Pharma US Inc $335 13 payments
  6. Novo Nordisk Inc $323 17 payments
  7. Allergan Inc. $304 13 payments
  8. Mylan Pharmaceuticals Inc. $151 7 payments
  9. Sumitomo Pharma America, Inc. $150 8 payments
  10. Agile Therapeutics, Inc. $143 9 payments
  11. Other $1,876 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,801 11 payments
  2. Food and Beverage $5,372 267 payments
  3. Education $142 3 payments
Products named General payments · program years 2019–2025
  1. LO LOESTRIN FE $388 24 payments
  2. ORILISSA $225 13 payments
  3. ANNOVERA $218 12 payments
  4. IMVEXXY $218 12 payments
  5. GEMTESA $217 11 payments
  6. Wegovy $161 8 payments
  7. ORIAHNN $156 9 payments
  8. Twirla $143 9 payments
  9. DAXXIFY $130 3 payments
  10. TRINTELLIX $127 6 payments
  11. Other $3,017 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,499

Median for Obstetrics & Gynecology: 65

Drug cost

$249,169

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

46.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 85 $108,115
Gemtesa Vibegron Brand 58 $55,125
Estradiol Generic 318 $23,134
Premarin Estrogens, Conjugated Brand 44 $20,263
Estring Estradiol Brand 20 $10,176
Imvexxy Estradiol Brand 23 $6,730
Progesterone Progesterone, Micronized Brand 168 $4,550
Estradiol (Twice Weekly) Estradiol Brand 28 $3,100
Yuvafem Estradiol Brand 13 $3,066
Metronidazole Generic 159 $2,906

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$71,318

Medicare's payments for the services billed

Medicare patients

385

Average age 74

Services billed

1,057

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 44%
Osteoporosis 19%
Ischemic heart disease 12%
Depression 12%
Cancer 11%
Diabetes 10%
Atrial fibrillation 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $53
$53 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $51
$51 58 —
ZEPBOUND
  • Lilly USA, LLC $42
$42 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $42
$42 — —
Veozah
  • Astellas Pharma US Inc $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record